- Home
- UWMC vs CDTX Comparison
UWMC vs CDTX Comparison
Compare UWMC & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- CDTX
- Stock Information
- Founded
- UWMC 1986
- CDTX 2012
- Country
- UWMC United States
- CDTX United States
- Employees
- UWMC N/A
- CDTX N/A
- Industry
- UWMC Finance: Consumer Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UWMC Finance
- CDTX Health Care
- Exchange
- UWMC Nasdaq
- CDTX Nasdaq
- Market Cap
- UWMC 1.4B
- CDTX 1.6B
- IPO Year
- UWMC N/A
- CDTX 2015
- Fundamental
- Price
- UWMC $5.36
- CDTX $106.93
- Analyst Decision
- UWMC Hold
- CDTX Strong Buy
- Analyst Count
- UWMC 8
- CDTX 11
- Target Price
- UWMC $6.32
- CDTX $91.60
- AVG Volume (30 Days)
- UWMC 9.4M
- CDTX 1.2M
- Earning Date
- UWMC 11-06-2025
- CDTX 11-06-2025
- Dividend Yield
- UWMC 7.41%
- CDTX N/A
- EPS Growth
- UWMC 112.84
- CDTX N/A
- EPS
- UWMC 0.07
- CDTX N/A
- Revenue
- UWMC $2,622,828,000.00
- CDTX N/A
- Revenue This Year
- UWMC $11.44
- CDTX N/A
- Revenue Next Year
- UWMC $17.88
- CDTX N/A
- P/E Ratio
- UWMC $81.39
- CDTX N/A
- Revenue Growth
- UWMC 13.45
- CDTX N/A
- 52 Week Low
- UWMC $3.80
- CDTX $10.14
- 52 Week High
- UWMC $7.60
- CDTX $106.63
- Technical
- Relative Strength Index (RSI)
- UWMC 32.86
- CDTX 74.35
- Support Level
- UWMC $5.28
- CDTX $96.35
- Resistance Level
- UWMC $6.31
- CDTX $106.63
- Average True Range (ATR)
- UWMC 0.26
- CDTX 6.70
- MACD
- UWMC -0.17
- CDTX 1.45
- Stochastic Oscillator
- UWMC 4.68
- CDTX 97.74
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.